Efficacy of Mazdutide on Fatty Pancreas

Fatty pancreas is a clinicopathological syndrome characterized by fat infiltration inpancreatic tissue. It can be classified into three categories based on etiology and riskfactors: ectopic pancreatic fat deposition due to overnutrition and metabolicdysfunction, secondary fatty replacement following pancreatic injury from various causes,and fatty pancreas associated with genetic or congenital diseases. Among these, excessivefat deposition within pancreatic tissue occurring against the backdrop of metabolicabnormalities is termed metabolic dysfunction‐associated fatty pancreas (MAFP), which iscommonly seen in individuals with overweight, obesity, or metabolic syndrome. MAFP canimpair both endocrine and exocrine pancreatic functions, increase the risks ofpancreatitis and glucose metabolism disorders, and significantly elevate the incidence ofpancreatic cancer. Currently, there are no approved specific pharmacotherapies for fattypancreas. Although lifestyle intervention serves as the foundational treatment, long‐termpatient adherence remains limited. Existing studies suggest that glucagon‐like peptide‐1receptor agonists (GLP‐1RAs) can effectively reduce visceral and ectopic fat deposition,lowering absolute pancreatic fat content by approximately 2%‐6%, thereby demonstratingpotential as therapeutic agents for MAFP. Mazdutide, a dual GLP‐1 receptor/glucagonreceptor (GLP‐1R/GCGR) agonist, synergistically activates dual metabolic pathways,reducing visceral fat accumulation while achieving potent weight loss. Based on itsunique mechanism of action and established evidence for weight reduction, mazdutide holdspromising application prospects for alleviating MAFP and managing metaboliccomorbidities. However, no dedicated studies have yet evaluated the impact of mazdutideon pancreatic fat content in obese patients.